Breaking
RAPS Euro Convergence: Top Regulatory Insights - Day 1European Research Revolution: Day 1 HighlightsRAPS Euro Convergence: Key Regulatory Updates - Day 1
🇪🇺 EMA

Metabolic Health

Page 1 • 1 item

Unlock global metabolic health market insights. NovaPharmaNews delivers critical pharma intelligence for investors, BD, and analysts.

Boehringer Ingelheim's Survodutide Achieves 16.6% Weight Loss in Phase 2 Obesity Trial, Outperforming Current Market Leaders
NewsObesity and Metabolic HealthApr 29, 2026

Boehringer Ingelheim's Survodutide Achieves 16.6% Weight Loss in Phase 2 Obesity Trial, Outperforming Current Market Leaders

Survodutide delivered 39.2 lb average weight loss in 76-week trial, potentially superior to Wegovy and Zepbound in competitive obesity market.

Dr. Amina Farouk